Estimation of Silanol Site Density of Synthesized C-S-H

瑛大, 岩浅; 義, 合田; 豊春, 名和; Elakneswaran, Yogarajah

doi:10.14250/cement.65.54

Cited by 1 publication

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the anatomic behavior of these hepatobiliary and pancreatic cancers may be partially responsible for the poor prognosis reported. Additionally, grade 3-4 neutropenia occurred in 90% of patients, followed by grade 3 nausea and anorexia in 33% and 24% of patients, respectively [22]. Taken together, these results demonstrate that perhaps cisplatin and etoposide have relatively low tumor activity in the pancreas and hepatobiliary tract, with a high incidence of negative side effects.…”

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 67%

“…Grounded in their recognized role in treating metastatic SCLC, cisplatin/carboplatin and etoposide have been used for decades in the treatment of GEPNECs [15,16,[21][22][23][24][25].…”

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 99%

“…Although the aforementioned regimen has been considered the default for all GEPNECs, the literature demonstrates that response may be site specific. Iwasa et al (2010) investigated the impact of cisplatin and etoposide on carcinoma arising from the hepatobiliary tract and pancreas [22]. This retrospective study examined 21 patients treated with this regimen (etoposide 100 mg/m 2 /day IV on days 1-3 and cisplatin 80 mg/m 2 IV on the first day every 3-4 weeks).…”

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 99%

See 2 more Smart Citations

Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma

et al. 2019

View full text Add to dashboard Cite

Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) are a rare neoplasm with a bleak prognosis. Currently there are little prospective data available for optimal treatment. This review discusses the current available regimens and the future direction for the treatment of GEPNECs. Treatment plans for GEPNECs are often adapted from those devised for small cell lung cancer; however, differences in these malignancies exist, and GEPNECs require their own treatment paradigms. As such, current first‐line treatment for GEPNECs is platinum‐based chemotherapy with etoposide. Studies show that response rate and overall survival remain comparable between cisplatin and carboplatin versus etoposide and irinotecan; however, prognosis remains poor, and more efficacious therapy is needed to treat this malignancy. Additional first‐line and second‐line treatment options beyond platinum‐based chemotherapy have also been investigated and may offer further treatment options, but again with suboptimal outcomes. Recent U.S. Food and Drug Administration approval of peptide receptor radionuclide therapy in low‐ and intermediate‐grade neuroendocrine tumors may open the door for further research in its usefulness in GEPNECs. Additionally, the availability of checkpoint inhibitors lends promise to the treatment of GEPNECs. This review highlights the lack of large, prospective studies that focus on the treatment of GEPNECs. There is a need for randomized control trials to elucidate optimal treatment regimens specific to this malignancy. Implications for Practice There are limited data available for the treatment of poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) because of the rarity of this malignancy. Much of the treatment regimens used in practice today come from research in small cell lung cancer. Given the poor prognosis of GEPNECs, it is necessary to have treatment paradigms specific to this malignancy. The aim of this literature review is to summarize the available first‐ and second‐line GEPNEC therapy, outline future treatments, and highlight the vast gap in the literature.

show abstract

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 67%

“…Grounded in their recognized role in treating metastatic SCLC, cisplatin/carboplatin and etoposide have been used for decades in the treatment of GEPNECs [15,16,[21][22][23][24][25].…”

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 99%

Section: Cisplatin/carboplatin + Etoposidementioning

confidence: 99%

See 1 more Smart Citation